What is OptimizeRx's unamortized debt issuance expense?

OptimizeRx (OPRX) reported unamortized debt issuance expense of $255K in Q1 2026.

How has OptimizeRx's unamortized debt issuance expense changed year-over-year?

OptimizeRx's unamortized debt issuance expense decreased by 80.4% year-over-year, from $1.3M to $255K.

What is the long-term trend for OptimizeRx's unamortized debt issuance expense?

Over 2 years (2023 to 2025), OptimizeRx's unamortized debt issuance expense has grown at a -45.4% compound annual growth rate (CAGR), from $2.06M to $614K.

OptimizeRx OPRX Unamortized Debt Issuance Expense

Unamortized Debt Issuance Expense at other companies

UMH

UMH PropertiesUMH

-$5.74M-63.6%

Blackstone Secured Lending FundBXSL

$18.7M-8.8%

Pathfinder BancorpPBHC

$71.99M+5.5%

LGI HomesLGIH

$20.84M—

Tarsus Pharmaceuticals, Inc.TARS

$3.52M0.0%

LTC PropertiesLTC

$4.42M+263%

Other financials

Income statement

See full

Revenue$19.8M-9.5%

Gross profit$14.9M+11.9%

Operating income$396.0K+119%

Net income-$495.0K+77.5%

EPS (diluted)-$0.03+75.0%

Balance sheet

See full

Cash & equivalents$20.2M+21.7%

Total debt$23.7M-27.7%

Total equity$129.6M+11.5%

Total assets$167.3M-0.3%

Cash flow

See full

Operating cash flow-$467.0K-112%

CapEx$21.0K-22.2%

Free cash flow-$488.0K-113%

Valuation

See full

Market cap$107.34M-54.1%

Enterprise value$110.88M-55.0%

P/E15.7×—

P/S1×-1.2×

Profitability

See full

Gross margin70%+14.1pp

Operating margin13.2%—

Net margin6.4%+3.6pp

FCF margin13.4%+4.8pp

Returns & leverage

See full

Return on equity5.6%+3.3pp

Debt / equity0.2×-0.1×

Current ratio5.4×+2.6×

Where this comes from

Reported directly by OptimizeRx in its filing.

Tagged under the XBRL concept us-gaap:UnamortizedDebtIssuanceExpense.

The official record: OptimizeRx’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about OptimizeRx's unamortized debt issuance expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OptimizeRx's unamortized debt issuance expense?: OptimizeRx (OPRX) reported unamortized debt issuance expense of $255K in Q1 2026.
How has OptimizeRx's unamortized debt issuance expense changed year-over-year?: OptimizeRx's unamortized debt issuance expense decreased by 80.4% year-over-year, from $1.3M to $255K.
What is the long-term trend for OptimizeRx's unamortized debt issuance expense?: Over 2 years (2023 to 2025), OptimizeRx's unamortized debt issuance expense has grown at a -45.4% compound annual growth rate (CAGR), from $2.06M to $614K.